Europäische Union - Deutsch - EMA (European Medicines Agency)

life molecular imaging gmbh - florbetaben (18f) - radionuclide imaging; alzheimer disease - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. neuraceq ist ein rp angegeben für die positronen-emissions-tomographie (pet) bildgebung von β-amyloid-neuritic plaque-dichte im gehirn erwachsener patienten mit kognitiven beeinträchtigungen, die bewertet wird, für die alzheimer-krankheit (ad) und andere ursachen kognitiver beeinträchtigung. neuraceq sollte verwendet werden, in verbindung mit einer klinischen bewertung. ein negativer scan zeigt spärlich oder keine plaques, die nicht im einklang mit einer diagnose von ad.

Europäische Union - Deutsch - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 und 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Schweiz - Deutsch - OFAG-BLW (Bundesamt für Landwirtschaft)

basf schweiz ag - kresoxim-methyl; epoxiconazole - scsuspensionskonzentrat - 11.5 %125 g/l; 11.5 %125 g/l; - fungizid ;

Schweiz - Deutsch - OFAG-BLW (Bundesamt für Landwirtschaft)

nufarm suisse sàrl - bromoxynil - scsuspensionskonzentrat - 32.5 %402 g/l; [als 39.1 % bromoxynil-butryrat (483 g/l), 0.98 % bromxynil-octanoat (12.1 g/l) und 0.68 % bromoxynil (8.4 g/l)]; - herbizid ;

Europäische Union - Deutsch - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hämoglobinurie, paroxysmal - selektive immunsuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alk - apis mellifica - injektionssuspension - apis mellifica - insects

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alk - apis mellifica; apis mellifica; apis mellifica; apis mellifica - injektionssuspension; injektionssuspension; injektionssuspension; injektionssuspension - apis mellifica ; apis mellifica ; apis mellifica ; apis mellifica - insects

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alk - venenum apis mellifera, auszug - pulver und lösungsmittel zur herstellung einer injektionslösung - 120 µg - venenum apis mellifera, auszug 0.12 mg - insects

Europäische Union - Deutsch - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - antiepileptika, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bencard allergie gmbh - bienengift-lyophilisat - trockensubstanz und lösungsmittel - bienengift-lyophilisat 100.µg